Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of intravenous and subcutaneous ustekinumab in pediatric ulcerative colitis
2019-004224-38Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in autoimmune colitis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Induction efficacy. Started Oct 2020; status: active.
02
Drugs
ustekinumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2019-004224-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004224-38.